Please replace all prior claims in the application with the following:

Claim 1 (currently amended): A liquid pharmaceutical composition ~~of~~ comprising a gamma-aminobutyric acid (GABA) ~~GABA~~ analog ~~compricing at least one polyhydric alcohol~~ and one or more polyhydric alcohols, each containing 2 to 6 carbon atoms, wherein the one or more polyhydric alcohols comprise about 25% to about 75% weight/volume of the composition and ~~wherein said~~ the composition has a pH of about 5.5 to about 7.0.

Claim 2 (currently amended): The composition according to claim 1, wherein the one or more polyhydric alcohols each ~~polyhydric alcohol~~ contains 3 to 5 carbon atoms ~~and wherein the content of polyhydric alcohol is about 25% to about 75% weight/volume (w/v)~~.

Claim 3 (currently amended): The composition according to claim 2, wherein the one or more polyhydric alcohols are ~~polyhydric alcohol is~~ selected from the group consisting of: glycerol, xylitol, sorbitol, mannitol, and a mixture of glycerol and xylitol, and wherein the one or more polyhydric alcohols comprise ~~content of polyhydric alcohol is~~ about 40% to about 75% weight/volume ~~(w/v)~~ of the composition.

Claim 4 (original): The composition according to claim 1, wherein the pH is about 6.0 to about 7.0.

Claim 5 (currently amended): The composition according to claim 1, comprising one or both of: ~~(a) an additional~~ a preservative~~;~~ and ~~(b) an additional~~ a flavor improver, wherein the flavor improver ~~which~~ does not contain an aldehyde or keto functionality.

Claim 6 (currently amended): A method for preparing a liquid pharmaceutical composition ~~of a GABA analog~~ comprising: ~~Step (1)~~ adding one or more polyhydric alcohols, each ~~a polyhydric alcohol~~ containing 2 to 6 carbon atoms, to water to form a first solution; ~~Step (2)~~ adding a gamma-aminobutyric acid ~~GABA~~ analog to the first solution ~~from Step (1)~~ to form a second solution; and ~~Step (3)~~ optionally~~,~~ adjusting the pH of the second solution ~~composition~~ to about 5.5 to about 7.0 to afford the liquid

pharmaceutical composition, wherein the one or more polyhydric alcohols comprise about 25% to about 75% weight/volume of the composition.

Claim 7 (currently amended): The method according to claim 6, wherein the one or more polyhydric alcohols are ~~polyhydric alcohol is~~ a mixture of glycerol and xylitol.

Claim 8 (currently amended): The method according to claim 6, wherein the ~~content of polyhydric alcohol is about 25% to 75% (w/v) and the~~ pH of the composition is about 6 to about 7.

Claim 9 (currently amended): A ~~two-component~~ liquid pharmaceutical composition ~~of a GABA analog~~ comprising ~~(a)~~ a first component, the first component comprising a powder mixture of a gamma-aminobutyric acid (GABA) ~~GABA~~ analog and a one or more solid polyhydric alcohols ~~alcohol~~; ~~(b)~~ and a second component comprising a liquid base, wherein the ~~powder~~ first and second components are combined ~~component from (a) is added to the liquid base from (b)~~ to afford a the liquid pharmaceutical composition in which the one or more polyhydric alcohols comprise about 25% to about 75% weight/volume of the composition.

Claim 10 (currently amended): A method for preparing a ~~two-component~~ liquid pharmaceutical composition, the method ~~of a GABA analog~~ comprising: ~~Step (1)~~ mixing a gamma-aminobutyric acid (GABA) ~~GABA~~ analog with a first solid polyhydric alcohol to afford a powder mixture; ~~Step (2)~~ mixing a second polyhydric alcohol with a sweetener and a flavor in water to afford a liquid base; and ~~Step (3)~~ adding the powder mixture to the liquid base to afford the liquid pharmaceutical composition, wherein the first and second polyhydric alcohols may be the same or different and together comprise about 25% to about 75% weight/volume of the composition.

Claim 11 (original): The method according to claim 10, wherein the GABA analog is gabapentin or pregabalin.

Claim 12 (original): The composition according to claim 1 or claim 9 wherein the GABA analog is gabapentin or pregabalin.

Claim 13 (currently amended): The composition according to claim 1 or claim 9 wherein ~~said~~ the composition has less than 0.5% by weight of the corresponding lactam of the GABA analog.

Claim 14 (currently amended): ~~An aqueous oral~~ A liquid pharmaceutical composition comprising ~~of~~ gabapentin or pregabalin, water, and one or more polyhydric alcohols, each ~~characterized by a content of at least 25% (w/v) of at least one polyhydric aliphatic alcohol~~ containing 2 to 6 carbon atoms, the composition having ~~and~~ a pH of about 5.5 to about 7.0 and containing, less than 0.5% weight/volume ~~(w/w)~~ of gabapentin lactam or pregabalin lactam, respectively, after storage at 2°C to 10°C ~~110°C~~ for 18 months to 2 years, wherein the one or more polyhydric alcohols comprise at least 25% weight/volume of the composition.

Claim 15 (currently amended): ~~The pharmaceutical composition according to claim 1 or claim 13 for the treatment of~~ A method of treating a subject suffering from cerebral diseases, including epilepsy, faintness attacks, hypokinesia and cranial traumas, neurodegenerative disorders, depression, mania and bipolar disorders, anxiety, panic, inflammation, renal colic, insomnia, gastrointestinal damage, incontinence, pain, including neuropathic pain, muscular pain, skeletal pain, and migraine, the method comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition according to claim 1 or claim 13.